Literature DB >> 20513024

Comparison of salvage and planned pharyngolaryngectomy with jejunal transfer for hypopharyngeal carcinoma after chemoradiotherapy.

Hideki Kadota1, Junichi Fukushima, Torahiko Nakashima, Yoshihiko Kumamoto, Sei Yoshida, Ryuji Yasumatsu, Hideki Shiratsuchi, Masaru Morita, Shizuo Komume.   

Abstract

OBJECTIVES/HYPOTHESIS: Salvage surgery after definitive chemoradiotherapy is often associated with a higher rate of perioperative complications and poor prognosis. The objective of this study is to examine the safety and efficacy of free jejunal transfer after salvage pharyngolaryngectomy for patients with locally recurrent hypopharyngeal carcinoma after definitive chemoradiotherapy. STUDY
DESIGN: A retrospective analysis of patients with advanced hypopharyngeal carcinoma who underwent pharyngolaryngectomy and reconstruction using free jejunum.
METHODS: Forty patients who underwent pharyngolaryngectomy with jejunal transfer were included in this study. Fourteen patients underwent surgery after definitive chemoradiotherapy (the salvage-surgery group), whereas 26 patients underwent surgery after planned preoperative chemoradiotherapy (the planned-surgery group). The perioperative conditions, mortality, morbidity, functional outcomes, and oncologic outcomes in each group were compared.
RESULTS: The patients in the salvage-surgery group lost an average of 9 kg in weight before surgery, which thus indicated a malnourished condition. However, the incidence of all perioperative complications did not differ significantly between the groups. All patients in both groups achieved oral intake without tube feeding, and the intervals to start oral intake were 12.8 days in the salvage-surgery group and 15.6 days in the planned-surgery group, which was not significantly different. The 5-year disease-free survival was 57.1% in the salvage-surgery group and 50.4% in the planned-surgery group, which was not significantly different.
CONCLUSIONS: Salvage pharyngolaryngectomy and jejunal transfer can be performed safely and reliably for patients with locally recurrent hypopharyngeal carcinoma, and it is an excellent option after a failure of definitive chemoradiotherapy.

Entities:  

Mesh:

Year:  2010        PMID: 20513024     DOI: 10.1002/lary.20887

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

Review 1.  Surgical strategies for esophageal cancer associated with head and neck cancer.

Authors:  Masaru Morita; Hiroshi Saeki; Shuhei Ito; Yasue Kimura; Nami Yamashita; Koji Ando; Yukiharu Hiyoshi; Eriko Tokunaga; Eiji Oki; Tetsuo Ikeda; Sei Yoshida; Torahiko Nakashima; Yoshihiko Maehara
Journal:  Surg Today       Date:  2013-08-30       Impact factor: 2.549

2.  Current reconstructive techniques following head and neck cancer resection using microvascular surgery.

Authors:  Takeharu Kanazawa; Shunji Sarukawa; Hirofumi Fukushima; Shoji Takeoda; Gen Kusaka; Keiichi Ichimura
Journal:  Ann Vasc Dis       Date:  2011-06-24

Review 3.  Surgical salvage of recurrent cancer of the head and neck.

Authors:  Mark Zafereo
Journal:  Curr Oncol Rep       Date:  2014-05       Impact factor: 5.075

4.  Upregulation of microRNA‑194‑5p inhibits hypopharyngeal carcinoma cell proliferation, migration and invasion by targeting SMURF1 via the mTOR signaling pathway.

Authors:  Shan Xu; Lian Hui; Ning Yang; Yan Wang; Ning Zhao; Xue-Jun Jiang
Journal:  Int J Oncol       Date:  2019-02-04       Impact factor: 5.650

Review 5.  Outcomes of anterolateral thigh flap reconstruction for salvage laryngopharyngectomy for hypopharyngeal cancer after concurrent chemoradiotherapy.

Authors:  Wei F Chen; Kai-Ping Chang; Chih-Hao Chen; Victor Bong-Hang Shyu; Huang-Kai Kao
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

6.  The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer.

Authors:  Shuhei Mayanagi; Tetsuro Onitsuka; Masahiro Nakagawa; Hiroshi Sato; Yuko Kitagawa; Yasuhiro Tsubosa
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.